Skip to content

Effect of Vaitarana Basti and Rasna Guggulu in Sciatica

Assessment Of Vaitarana Basti And Rasna Guggulu In The Management Of Pain In Gridhrasi (Sciatica) A Randomized Controlled Clinico Experimental Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/03/012346
Enrollment
90
Registered
2018-03-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M543- Sciatica

Interventions

Intervention1: Group A: In this group Vaitarana basti will be given for 16 days accompanied by oral administration of Rasna guggulu, as a Shamana drug in the dose of 500 mg, 2 tablets, thrice/day with

Sponsors

IPGT and RA Gujarat Ayurved university Jamnagar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of Gridhrasi with symptoms like Ruja, Stambha, Suptata, Spandana, Tandra, Gaurava, Arochaka. Patients of age group between 20 and 65 years, belonging to both sex. Patients indicated for basti karma Willing to sign the consent for study participation.

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes mellitus, hypertension, tuberculosis of spine and hip joint, malignancy of spine or other organs Fracture related to spine Cardiac diseases (ischemic heart disease, coronary artery disease, myocardial infarction etc.) Anemia (hemoglobin % Pregnancy. Patients contraindicated for basti.

Design outcomes

Primary

MeasureTime frame
Assessment will be done on the basis of special designed proformaTimepoint: 7 days

Secondary

MeasureTime frame
Assessment will be done on the basis of special designed proformaTimepoint: 60 days

Countries

India

Contacts

Public ContactDr Praveen Kumar K S

IPGT and RA Jamnagar

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026